Maria Laura Amaya
Title | Asst Professor |
---|
Institution | University of Colorado Denver - Anschutz Medical Campus |
---|
Department | SOM-MED |
---|
Phone | 720/766-9786 |
---|
|
|
|
Research IK2BX005603 (AMAYA, MARIA LAURA)Apr 1, 2022 - Mar 31, 2027 NIH Identifying the Role of the IL-6/STAT3 Signaling Pathway in Higher-risk Myelodysplastic Syndrome Role: Principal Investigator |
| F31DK094650 (AMAYA, MARIA LAURA)Jul 25, 2012 - Jul 24, 2015 NIH The Role of Mi2/NuRD Complex on the Expression of Human Gamma-Globin Gene Role: Principal Investigator |
Bibliographic
-
Sheth AI, Engel K, Tolison H, Althoff MJ, Amaya ML, Krug A, Young T, Pei S, Patel SB, Minhajuddin M, Winters A, Miller R, Shelton I, St-Germain J, Ling T, Jones C, Raught B, Gillen A, Ransom M, Staggs S, Smith CA, Pollyea DA, Stevens BM, Jordan CT. Targeting Acute Myeloid Leukemia Stem Cells Through Perturbation of Mitochondrial Calcium. bioRxiv. 2023 Oct 03. PMID: 37873284.
-
Gutman JA, Winters A, Kent A, Amaya M, McMahon C, Smith C, Jordan CT, Stevens B, Minhajuddin M, Pei S, Schowinsky J, Tobin J, O'Brien K, Falco A, Taylor E, Brecl C, Zhou K, Ho P, Sohalski C, Dell-Martin J, Ondracek O, Abbott D, Pollyea DA. Higher-dose venetoclax with measurable residual disease-guided azacitidine discontinuation in newly diagnosed acute myeloid leukemia. Haematologica. 2023 10 01; 108(10):2616-2625. PMID: 37051756.
-
Pei S, Shelton IT, Gillen AE, Stevens BM, Gasparetto M, Wang Y, Liu L, Liu J, Brunetti TM, Engel K, Staggs S, Showers W, Sheth AI, Amaya ML, Minhajuddin M, Winters A, Patel SB, Tolison H, Krug AE, Young TN, Schowinsky J, McMahon CM, Smith CA, Pollyea DA, Jordan CT. A Novel Type of Monocytic Leukemia Stem Cell Revealed by the Clinical Use of Venetoclax-Based Therapy. Cancer Discov. 2023 09 06; 13(9):2032-2049. PMID: 37358260.
-
Kent A, Schwartz M, McMahon C, Amaya M, Smith CA, Tobin J, Marciano K, Rezac R, Bosma G, Pollyea DA, Gutman JA. Venetoclax is safe and tolerable as post-transplant maintenance therapy for AML patients at high risk for relapse. Bone Marrow Transplant. 2023 08; 58(8):849-854. PMID: 37185614.
-
Islam N, Reuben JS, Dale J, Gutman J, McMahon CM, Amaya M, Goodman B, Toninato J, Gasparetto M, Stevens B, Pei S, Gillen A, Staggs S, Engel K, Davis S, Hull M, Burke E, Larchick L, Zane R, Weller G, Jordan C, Smith C. Machine Learning-Based Exploratory Clinical Decision Support for Newly Diagnosed Patients With Acute Myeloid Leukemia Treated With 7 + 3 Type Chemotherapy or Venetoclax/Azacitidine. JCO Clin Cancer Inform. 2022 09; 6:e2200030. PMID: 36194842.
-
Nie Y, Kent A, Do M, Amaya M, Klein C, Thienelt C. Atraumatic Splenic Rupture due to Chronic Myelomonocytic Leukemia Treated with Partial Splenic Artery Embolization. Case Rep Oncol. 2022 Jan-Apr; 15(1):277-284. PMID: 35529292.
-
Amaya ML, Inguva A, Pei S, Jones C, Krug A, Ye H, Minhajuddin M, Winters A, Furtek SL, Gamboni F, Stevens B, D'Alessandro A, Pollyea DA, Reigan P, Jordan CT. The STAT3-MYC axis promotes survival of leukemia stem cells by regulating SLC1A5 and oxidative phosphorylation. Blood. 2022 01 27; 139(4):584-596. PMID: 34525179.
-
Cherry EM, Abbott D, Amaya M, McMahon C, Schwartz M, Rosser J, Sato A, Schowinsky J, Inguva A, Minhajuddin M, Pei S, Stevens B, Winters A, Jordan CT, Smith C, Gutman JA, Pollyea DA. Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia. Blood Adv. 2021 12 28; 5(24):5565-5573. PMID: 34610123.
-
Abbott D, Cherry E, Amaya M, McMahon C, Schwartz M, Winters A, Schowinsky J, Jordan CT, Smith C, Gutman JA, Pollyea DA. The propriety of upgrading responses to venetoclax?+?azacitidine in newly diagnosed patients with acute myeloid leukemia. Leuk Lymphoma. 2021 06; 62(6):1466-1473. PMID: 33375853.
-
Ye H, Minhajuddin M, Krug A, Pei S, Chou CH, Culp-Hill R, Ponder J, De Bloois E, Schniedewind B, Amaya ML, Inguva A, Stevens BM, Pollyea DA, Christians U, Grimes HL, D'Alessandro A, Jordan CT. The Hepatic Microenvironment Uniquely Protects Leukemia Cells through Induction of Growth and Survival Pathways Mediated by LIPG. Cancer Discov. 2021 02; 11(2):500-519. PMID: 33028621.
-
Jones CL, Stevens BM, Pollyea DA, Culp-Hill R, Reisz JA, Nemkov T, Gehrke S, Gamboni F, Krug A, Winters A, Pei S, Gustafson A, Ye H, Inguva A, Amaya M, Minhajuddin M, Abbott D, Becker MW, DeGregori J, Smith CA, D'Alessandro A, Jordan CT. Nicotinamide Metabolism Mediates Resistance to Venetoclax in Relapsed Acute Myeloid Leukemia Stem Cells. Cell Stem Cell. 2020 11 05; 27(5):748-764.e4. PMID: 32822582.
-
Amaya ML, Jimeno A, Kamdar M. Polatuzumab vedotin to treat relapsed or refractory diffuse large B-cell lymphoma, in combination with bendamustine plus rituximab. Drugs Today (Barc). 2020 Apr; 56(4):287-294. PMID: 32309823.
-
Pei S, Pollyea DA, Gustafson A, Stevens BM, Minhajuddin M, Fu R, Riemondy KA, Gillen AE, Sheridan RM, Kim J, Costello JC, Amaya ML, Inguva A, Winters A, Ye H, Krug A, Jones CL, Adane B, Khan N, Ponder J, Schowinsky J, Abbott D, Hammes A, Myers JR, Ashton JM, Nemkov T, D'Alessandro A, Gutman JA, Ramsey HE, Savona MR, Smith CA, Jordan CT. Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Patients with Acute Myeloid Leukemia. Cancer Discov. 2020 04; 10(4):536-551. PMID: 31974170.
-
Pollyea DA, Amaya M, Strati P, Konopleva MY. Venetoclax for AML: changing the treatment paradigm. Blood Adv. 2019 12 23; 3(24):4326-4335. PMID: 31869416.
-
Amaya ML, Pollyea DA. Targeting the IDH2 Pathway in Acute Myeloid Leukemia. Clin Cancer Res. 2018 10 15; 24(20):4931-4936. PMID: 29769206.
-
Amaya M, Desai M, Gnanapragasam MN, Wang SZ, Zu Zhu S, Williams DC, Ginder GD. Mi2?-mediated silencing of the fetal ?-globin gene in adult erythroid cells. Blood. 2013 Apr 25; 121(17):3493-501. PMID: 23444401.
-
Gnanapragasam MN, Scarsdale JN, Amaya ML, Webb HD, Desai MA, Walavalkar NM, Wang SZ, Zu Zhu S, Ginder GD, Williams DC. p66Alpha-MBD2 coiled-coil interaction and recruitment of Mi-2 are critical for globin gene silencing by the MBD2-NuRD complex. Proc Natl Acad Sci U S A. 2011 May 03; 108(18):7487-92. PMID: 21490301.
-
Watts AG, Damager I, Amaya ML, Buschiazzo A, Alzari P, Frasch AC, Withers SG. Trypanosoma cruzi trans-sialidase operates through a covalent sialyl-enzyme intermediate: tyrosine is the catalytic nucleophile. J Am Chem Soc. 2003 Jun 25; 125(25):7532-3. PMID: 12812490.
This graph shows the total number of publications by year, by first, middle/unknown, or last author.
To see the data from this visualization as text, click here.
Year | Publications |
---|
2003 | 1 | 2011 | 1 | 2013 | 1 | 2018 | 1 | 2019 | 1 | 2020 | 5 | 2021 | 1 | 2022 | 3 | 2023 | 4 |
To return to the timeline, click here.
|
Amaya's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|